Making <scp>HPV</scp> vaccination available to girls everywhere

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

2015 • 1,192 citations

Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis

2016 • 705 citations

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 654 citations

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

2007 • 581 citations

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

2015 • 579 citations

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

2017 • 379 citations

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

2011 • 329 citations

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2015

2016 • 320 citations

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

2015 • 283 citations

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study

2014 • 232 citations

Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme

2012 • 231 citations

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

2014 • 227 citations

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries

2011 • 224 citations

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

2015 • 221 citations

Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions

2015 • 197 citations

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

2008 • 190 citations

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

2015 • 188 citations

Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old

2010 • 179 citations

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

2016 • 171 citations

Human papillomavirus vaccines: WHO position paper, May 2017.

2017 • 170 citations

Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis

2012 • 130 citations

Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania

2015 • 130 citations

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial

2017 • 86 citations

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines

2010 • 85 citations

Progress in HPV vaccination in low‐ and lower‐middle‐income countries

2017 • 79 citations

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up ofthree cohorts from randomized trials

2017 • 76 citations

Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict

2015 • 73 citations

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

2015 • 71 citations

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

2013 • 57 citations

Manufacturing costs of HPV vaccines for developing countries

2016 • 56 citations

Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects

2017 • 53 citations

Systematic review of human papillomavirus vaccine coadministration

2014 • 52 citations

Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India

2010 • 50 citations

Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014

2016 • 47 citations

Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan Africa

2013 • 43 citations

Primary Prevention of HPV through Vaccination: Update on the Current Global Status

2016 • 37 citations

Argentina’s Successful Implementation Of A National Human Papillomavirus Vaccination Program

2016 • 15 citations